You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.
The Swiss firm will offer 17,647,059 of its ordinary shares at $4.25 per share. It previously said it would offer $60 million worth of its shares.
The company intends to use the proceeds of the offering primarily to fund the ongoing development and commercialization of its MosaiQ diagnostic platform.
The firm also expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million worth of shares of its common stock.
The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.
The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.
The firm will use the proceeds for working capital and other general corporate purposes, with the potential to acquire or invest in complementary businesses, technologies, or assets.
Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.